Table 3.
Serum lipids (mg/dl) at the end of 4 weeks Benecol ® and at the end of placebo treatment
| Benecol | Placebo | Benecol® vs. placebo | p | ||||
|---|---|---|---|---|---|---|---|
| Mean | (95% CI) | Mean | (95% CI) | Mean | (95% CI) | ||
| Total cholesterol (mg/dL) | 205.5 | (197.9 – 213.2) | 221.1 | (212.8 – 229.4) | -15,6 | (-24.2 to -6.9) | 0.001 |
| HDL cholesterol (mg/dL) | 49.6 | (45.8 - 53,4) | 49.5 | (45.1 – 53.9) | 0.1 | (-4.0 to 4.3) | 0.95 |
| LDL cholesterol measured (mg/dL) | 108.7 | (102.3 – 115.0) | 120.7 | (113.5 – 127.8) | -12.0 | (-16.5 to -7.5) | <0.001 |
| LDL cholesterol calculated (mg/dL) | 125.8 | (117.9 – 133.7) | 142.2 | (134.0 – 150.4) | -16.4 | (-23.4 to -9.3) | <0.001 |
| Non-HDL cholesterol (mg/dL) | 155.9 | (147.3 - 164.5) | 171.6 | (162.5 – 180.7) | -15.7 | (-23.0 to -8.3) | <0.001 |
| TG3 (mg/dL) | 176.4 | (137.2 – 215.7) | 168.8 | (138.7 – 198.9) | 7.6 | (-23.9 to 39.1) | 0.63 |
3The distribution of TG was skew to the right.
After logarithmic transformation, the geometric means were 146.2 in Benecol® and 149.4 in placebo (p = 0.76).